Stock Analysis
GLOBUS MEDICAL INCGMED
P/E 19.24×· 5Y range 17.76–248.68×· bottom 5% of history
Sector: Healthcare · Industry: Surgical & Medical Instruments & Apparatus
AnalystsStrong Buy23 analystsP/E 19.2× sits at the 5th percentile of its 5.059548254620124-year history.
PMP Verdict
Strong business, attractive price
Strengths
- Growth95
- Quality95
High-quality business at an attractive price.
Market context
-2.7% today· Z 2.1σ
Bull Case
- ✓Piotroski F-Score 8/9 — high earnings quality
- ✓Altman Z 10.2 — safe-zone balance sheet
- ✓Revenue CAGR 32.3% — durable top-line growth
- ✓P/E 19.2× at bottom 5% of 5-year history
What's happening with GMED
Profile
Strong growth, earnings quality and valuation.
How is each axis scored?
- Valuation75/100 · Strong
- P/E vs own history (5th pct)25/25
- FCF yield (7.3%)20/25
- P/S (3.3x)20/25
- EV/EBIT (n/a)10/25
- Growth95/100 · Strong
- Revenue CAGR (32.3%)25/25
- Net income CAGR (37.8%)25/25
- EPS CAGR 5Y (28.5%)25/25
- Fwd implied growth (25.4%)20/25
- Profitability64/100 · Moderate
- ROIC (12.6%)12/25
- ROE (11.7%)12/25
- Net margin (17.0%)20/25
- Operating margin (20.3%)20/25
- Financial Health60/100 · Moderate
- Altman Z (10.23)25/25
- Current ratio (4.26)25/25
- Interest coverage (3.5x)10/25
- Net cash / debt (n/a)0/25
- Quality95/100 · Strong
- Piotroski F (8/9)25/25
- Beneish M (-2.72)25/25
- FCF conversion (141%)25/25
- Margin stability (σ 7.6%)20/25
- Moat68/100 · Moderate
- ROIC >12% years (3/10 yrs)6/25
- Median gross margin (74.6%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 4.1%)12/25
About GLOBUS MEDICAL INC
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. Show more
The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
Headquarters: AUDUBON, PA · Employees: 6,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
75B+P/E (TTM)19.2xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 5Y history: 17.8x–248.7x · 5th pct
P/FCF14.1xA
Grade A: CheapPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield7.3%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 1.4%–7.7% · 97th pct
P/S (TTM)3.28xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 2.7x–9.0x · 11th pct
EV/EBITDA13.2xB
Grade B: FairEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales3.2xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E15.3xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio2.25xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio0.40A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
64BROIC12.6%C
Grade C: AverageNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE11.7%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA10.0%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin17.0%A
Grade A: HighNet Income / Revenue
Operating Margin20.3%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin68.5%A
Grade A: PremiumGross Profit / Revenue
FCF Margin24.0%A
Grade A: HighFCF / Revenue
True FCF Margin22.5%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
95A+Revenue CAGR32.3%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR37.8%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)28.5%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth25.4%C
Grade C: MedAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+30.4%D
Grade D: DilutiveShare count change over 5Y
SBC / Net Income9.1%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.6%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
60BAltman Z-Score10.23A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio4.26xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.78xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage3.5xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.00xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
95A+Piotroski F-Score8/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.72A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion141.1%A
Grade A: StrongFCF / Net Income
Margin Stability7.6%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue4.9%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.59xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
TOBIN JAMES R Filed | TOBIN JAMES R | Option exercise | -15000 | |
TOBIN JAMES R Filed | TOBIN JAMES R | SellOpen market sale | -30000 | |
TOBIN JAMES R Filed | TOBIN JAMES R | Option exercise | +15.0K | |
TOBIN JAMES R Filed | TOBIN JAMES R | Option exercise | +15.0K | |
ZARRILLI STEPHEN T Filed | ZARRILLI STEPHEN T | Option exercise | -25000 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
ZARRILLI STEPHEN T Filed | ZARRILLI STEPHEN T | SellOpen market sale | -25000 | |
ZARRILLI STEPHEN T Filed | ZARRILLI STEPHEN T | Option exercise | +25.0K | |
Davidar David D Filed | Davidar David D | Gift | -2500 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
68BROIC >12% Years3/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)74.6%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor4.1%C
Grade C: ModerateWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$3.99
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$4.43
Cash & short-term investments per share (Finnhub)
Book Value / Share$35.52
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$557.24M
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$4.57B
Shareholders' equity (book value)
Asset / Liability7.27xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$10.30B
Current Market Capitalization
Beta0.97B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: GLOBUS MEDICAL INC (GMED)
GMED is down 2.70% at the last close. GLOBUS MEDICAL INC meets 8 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 10.23 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.72 suggests a low likelihood of earnings manipulation.
- Revenue has compounded at roughly 32% annually, with net income growing about 38% per year — a strong growth profile.
- GLOBUS MEDICAL INC converts about 24% of revenue into free cash flow — strong cash generation.
- At a valuation score of 75/100, GMED trades near the cheapest end of its own historical range (P/E 19.2).
See how GMED ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all GMED moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 16 | Regular | 76.60 | -2.85% | -2.19 |
| Oct 16 | After-hours | 76.71 | -2.70% | -2.09 |
| Oct 15 | Regular | 79.22 | +3.81% | 2.77 |
| Oct 15 | After-hours | 78.84 | +3.32% | 2.40 |
| Oct 7 | Regular | 73.81 | -3.43% | -3.28 |
Frequently Asked Questions about GMED
What is the current GLOBUS MEDICAL INC (GMED) stock price?
GMED is trading at $76.71 at the last market close, down 2.70% on the session. PreMarketPrice tracks GMED pre-market, intraday and after-hours prices.
Is GMED stock a buy right now?
PreMarketPrice's quantitative model rates GLOBUS MEDICAL INC's financial health at 60/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is GMED stock overvalued?
GLOBUS MEDICAL INC trades at a trailing P/E of 19.2 and our valuation score rates it 75/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does GLOBUS MEDICAL INC report earnings?
No confirmed earnings date is currently scheduled for GMED. The Earnings section lists recent reports and updates as dates are announced.
What sector does GLOBUS MEDICAL INC operate in?
GLOBUS MEDICAL INC operates in the Healthcare sector, within the Surgical & Medical Instruments & Apparatus industry. The Related Stocks section lists sector peers for comparison.
What does GLOBUS MEDICAL INC do?
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers.
About GLOBUS MEDICAL INC (GMED) Stock
GLOBUS MEDICAL INC (GMED) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry. As of the latest update, GLOBUS MEDICAL INC is trading at $76.71, down 2.70% on the day with a market capitalization of $10.3 billion. The financial health score for GMED is 60/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for GMED stock.
GMED Stock Analysis & Key Metrics
On PreMarketPrice, you can track GLOBUS MEDICAL INC (GMED) across multiple dimensions:
- Pre-market price & movement: Real-time GMED stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for GMED with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for GLOBUS MEDICAL INC across multiple reporting periods.
- Financial health score: A composite score of 60/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for GMED.
- Sector peers: Compare GMED against 6 other healthcare stocks on key financial metrics.
Is GMED a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate GLOBUS MEDICAL INC (GMED) as an investment. The financial health score of 60/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.GLOBUS MEDICAL INC (GMED) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.